ArticleActa ophthalmologica2026
Minocycline and bone marrow-derived mononuclear cells as potential therapeutics for hereditary retinal degenerations.
Article in Acta ophthalmologica, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Minocycline and bone marrow-derived mononuclear cells as potential therapeutics for hereditary retinal degenerations.Acta ophthalmologica · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
purposeTo assess in Royal College of Surgeons (RCS) rats if the combination of two previously documented neuroprotective strategies: minocycline administration and bone marrow-derived mononuclear cells (BM-MNCs) intravitreal transplantation, offers enhanced neuroprotection compared with each treatment alone.
methodsForty-eight homozygous pigmented RCS rats were divided into four groups: control, intravitreal BM-MNC transplantation, systemic minocycline treatment or combined therapy. Treatments were administered at postnatal day (P) 27-28. Animals were evaluated in vivo by spectral domain optical coherence tomography (SD-OCT) at P28, P35 and P51. Retinal sections were analysed for photoreceptor survival (outer nuclear layer [ONL] cell counts), synaptic preservation (Bassoon immunoreactivity), microglial activation (Iba-1+ cells) and macroglial reactivity (glial fibrillary acidic protein [GFAP] expression).
resultsBoth BM-MNC and minocycline monotherapies significantly preserved total and outer retinal thicknesses and increased ONL nuclei counts compared with controls. Combined treatment yielded superior protection at both P35 and P51. Minocycline alone or in combination significantly reduced microglial cell activation, while BM-MNCs alone or in combination significantly reduced GFAP expression. Synaptic integrity in the outer plexiform layer, assessed via Bassoon labelling, was significantly better preserved in treated animals, with the highest levels observed in the combined therapy group.
conclusionsMinocycline and BM-MNCs provide complementary neuroprotective effects in the RCS rat model. While minocycline reduces microglial activation, BM-MNCs modulate macroglial response. Their combination enhances photoreceptor survival and synaptic preservation more effectively than either treatment alone. These findings support the therapeutic potential of combining pharmacological and cell-based interventions in hereditary retinal degenerations.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.